Also, consolidation with anti-PD-L1 after concurrent chemoradiotherapy has significantly reduced the risk of recurrence for locally advanced stage III NSCLC and it is established as standard of care in this setting (36). This evidence concerns the gene CD274 and non-small cell lung carcinoma.